Free Newsletter
AstraZeneca: Just a bit of outsourcing
Did we say that? AstraZeneca is now denying any intention of outsourcing all its manufacturing, saying the EVP who'd called production "not a core activity" was misquoted. But, the company says, it will begin looking to contract manufacturers in India and China for some active ingredients in various meds.
-read this article in Pharmafocus
Related Articles:
AstraZeneca to outsource manufacturing. Report
Americans distrust drugs from China, India. Report
Research points to rapid growth of R&D outsourcing. Report
China pushes drug development as R&D soars. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: